HCG (Human Chorionic Gonadotropin)

Product Overview

HCG is a hormone primarily produced during pregnancy, responsible for maternal recognition of pregnancy and detectable by pregnancy tests. HCG levels double every 2–3 days during early pregnancy, peaking around 6–8 weeks. Beyond pregnancy, HCG has significant clinical applications: certain tumors produce HCG (making it a valuable tumor marker), and its structural similarity to luteinizing hormone (LH) enables it to stimulate testosterone production and spermatogenesis.

Mechanism of Action

HCG regulates expression of EG-VEGF (endocrine gland-derived vascular endothelial growth factor) and its receptors PROKR1 and PROKR2. Due to structural similarity to LH, HCG acts as an LH agonist, stimulating testosterone production in Leydig cells and directly promoting spermatogenesis.

Key Benefits

Tumor Marker Utility — β-HCG is widely used in oncology for diagnosing and monitoring germ cell tumors, choriocarcinoma, and other malignancies. Combined with alpha-fetoprotein (AFP), it provides high sensitivity and specificity. Normal reference range for men: 0–5 mIU/mL.

Hormonal Balance Support — Stimulates endogenous testosterone production by mimicking LH, helping restore hormonal equilibrium in age-related decline. Addresses root causes rather than symptoms, improving physical vitality, emotional resilience, and cognitive function.

Fertility Enhancement — Stimulates Leydig cells to produce testosterone essential for spermatogenesis. Supports sperm maturation and motility, increasing conception likelihood. Integrated into treatment protocols for hypogonadotropic hypogonadism.

Weight Management Support — May act on the hypothalamus to regulate appetite and mobilize adipose tissue stores when combined with structured dietary programs. Promotes utilization of stored fat while preserving lean muscle mass.

References

1. Gregory JJ, Finlay JL. Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers. *Drugs.* 1999;57(4):463–467.
2. Chan CC, et al. Bioavailability of hCG after intramuscular or subcutaneous injection in obese and non-obese women. *Hum Reprod.* 2003;18(11):2294–2297.
3. Butler SA, et al. The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin. *Br J Cancer.* 2000;82(9):1553–1556.